EcoDrugPlus

Kras Proto-Oncogene, Gtpase

Ensembl ID : ENSMMUG00000015381
Gene Symbol: KRAS
5 Cross references
201 Possible Orthologues:


Display Options: Drug type Mechanism of Action Route of Adminstration Status Therapeutic Area Therapeutic Indication

Lck Proto-Oncogene, Src Family Tyrosine Kinase

Ensembl ID : ENSMMUG00000040694
Gene Symbol: LCK
5 Cross references
120 Possible Orthologues:


Display Options: Drug type Mechanism of Action Route of Adminstration Status Therapeutic Area Therapeutic Indication

Lyn Proto-Oncogene, Src Family Tyrosine Kinase

Ensembl ID : ENSMMUG00000014149
Gene Symbol: LYN
5 Cross references
202 Possible Orthologues:


Display Options: Drug type Mechanism of Action Route of Adminstration Status Therapeutic Area Therapeutic Indication

Malt1 Paracaspase

Ensembl ID : ENSMMUG00000014235
Gene Symbol: MALT1
5 Cross references
195 Possible Orthologues:


Display Options: Drug type Mechanism of Action Route of Adminstration Status Therapeutic Area Therapeutic Indication

Mapk Activated Protein Kinase 2

Ensembl ID : ENSMMUG00000023567
Gene Symbol: MAPKAPK2
5 Cross references
233 Possible Orthologues:


Display Options: Drug type Mechanism of Action Route of Adminstration Status Therapeutic Area Therapeutic Indication

Mapk Activated Protein Kinase 5

Ensembl ID : ENSMMUG00000022353
Gene Symbol: MAPKAPK5
5 Cross references
179 Possible Orthologues:


Display Options: Drug type Mechanism of Action Route of Adminstration Status Therapeutic Area Therapeutic Indication

Mapk Interacting Serine/threonine Kinase 1

Ensembl ID : ENSMMUG00000020162
Gene Symbol: MKNK1
5 Cross references
166 Possible Orthologues:


Display Options: Drug type Mechanism of Action Route of Adminstration Status Therapeutic Area Therapeutic Indication

Mapk Interacting Serine/threonine Kinase 2

Ensembl ID : ENSMMUG00000011265
Gene Symbol: MKNK2
5 Cross references
220 Possible Orthologues:


Display Options: Drug type Mechanism of Action Route of Adminstration Status Therapeutic Area Therapeutic Indication

Mcl1 Apoptosis Regulator, Bcl2 Family Member

Ensembl ID : ENSMMUG00000053525
Gene Symbol: MCL1
5 Cross references
236 Possible Orthologues:


Display Options: Drug type Mechanism of Action Route of Adminstration Status Therapeutic Area Therapeutic Indication

Mdm2 Proto-Oncogene

Ensembl ID : ENSMMUG00000055447
Gene Symbol: MDM2
5 Cross references
258 Possible Orthologues:


Display Options: Drug type Mechanism of Action Route of Adminstration Status Therapeutic Area Therapeutic Indication

Met Proto-Oncogene, Receptor Tyrosine Kinase

Ensembl ID : ENSMMUG00000006779
Gene Symbol: MET
5 Cross references
211 Possible Orthologues:


Display Options: Drug type Mechanism of Action Route of Adminstration Status Therapeutic Area Therapeutic Indication

Mpl Proto-Oncogene, Thrombopoietin Receptor

Ensembl ID : ENSMMUG00000003148
Gene Symbol: MPL
5 Cross references
186 Possible Orthologues:


Display Options: Drug type Mechanism of Action Route of Adminstration Status Therapeutic Area Therapeutic Indication

Select Keywords:


PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains. Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).

PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains.

Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).